Q1 2020 - PCIB`s første kvartal hvor vi gikk i PLUSS med 4,4 mill NOK
Hvor mye går vi pluss ved Q2 med tanke på eventuelle deals innen NAc, VACC eller Chem
In the quarter exchange rate fluctuation on cash deposits placed in Euro generated a positive accounting effect of NOK 19.9 million. From inception in October 2018 the Euro deposits have had a net positive accounting effect of NOK 27.4 million.
In short, the main priorities of PCI Biotech at this time are to:
• Effectively drive the fimaCHEM clinical development programme in inoperable extrahepatic bile duct cancer towards the market
• Implement the strategy for the next phase of development for fimaVACC
• Manage alliance and partnering activities across all commercially interesting areas for the PCI platform
Vet at fokuset er på NAc og AZ nå men mener at VACC går under radaren til de fleste hær
New US patents granted These US patents secure protection until 2035
In January 2020, a US patent was granted providing a broad coverage for the combination of various cytokines with the fimaVACC technology.
Cytokines are small signalling proteins secreted by immune cells to regulate immunity
Used to modulate appropriate and effective vaccine responses
In March 2020, a further US patent was granted providing a broad coverage for the combination of the fimaVACC technology with a new important class of adjuvants, called toll like receptor agonists.
TLRs sense pathogen-associated structures as danger signals
TLR agonists represent promising vaccine adjuvants
These patents are important for PCI Biotech’s development strategy, as it supplements the company’s ability to potentially generate an internal future vaccine pipeline, in addition to bringing value for the fimaVACC technology in partnering efforts.
1H 2020 ✓fimaVACC Phase I results published in scientific journal
Må si jeg gleder meg til denne som vil komme innen utgangen av juni
Potential COVID-19 opportunities
Significant efforts are being invested by the global health community to research and develop potential treatments against COVID-19. Most vaccine companies are currently focused on reaching the clinic with their own established technologies and may not be open for the inclusion of new technologies in the short term.
PCI Biotech is nevertheless closely monitoring and exploring potential opportunities to contribute to these efforts, as the characteristics of the PCI technology may fit well with the medical needs
postet denne igår uten noen respons, noen som har noen tanker rundt denne?
Better understanding of Covid-19’s impact on the immune system gives hope an existing drug might aid recovery.
They have looked at immune cells in the blood of 60 Covid-19 patients and found an apparent crash in the numbers of T-cells.
Prof Adrian Hayday from the Crick Institute said it was a “great surprise” to see what was happening with the immune cells.
"They’re trying to protect us, but the virus seems to be doing something that’s pulling the rug from under them, because their numbers have declined dramatically.